Work

336P: Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(25)00528-3

Authors: Y. Cheng, Q. Wang, J. Fang, A. Shi, L. Wu, S. Lu, Z. Zhu, Y. Liu, Q. Wang, H. Jiang, X. Li, M. Wang, Y. Chen, H. Lu, Y. Duan, R. Meng, Y. Yang, Y. Chen, Y.S. Olivo, S. Senan

Institutions: Jilin Province Tumor Hospital, University of Electronic Science and Technology of China, Zhengzhou University, Sichuan Cancer Hospital, Henan Cancer Hospital, Peking University Cancer Hospital, Central South University, Hunan Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Fudan University Shanghai Cancer Center, First Hospital of China Medical University, First Affiliated Hospital of Bengbu Medical College, Liaoning Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Tongji Hospital, Huazhong University of Science and Technology, Central Hospital of Wuhan, Army Medical University, Xinqiao Hospital, Wuhan Union Hospital, AstraZeneca (United States), Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam

Language: French

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Sanofi, Norges Teknisk-Naturvitenskapelige Universitet

OpenAlex ID: W4408989230

FWCI: 0.737

Cites:

Cited by: 2

Related to: 10